Overview

• Eli Lilly will donate insulin to 15 clinics across Minnesota and cap monthly insulin costs at $35 for the next five years.
• The settlement is expected to benefit as many as 500,000 Minnesota residents, regardless of their insurance status.
• Litigation against other insulin manufacturers, Sanofi-Aventis and Novo Nordisk, is still ongoing.
• The agreement builds on previous efforts to make insulin more affordable, including federal price caps for Medicare patients.
• The settlement comes amid a surge in diabetes rates in Minnesota, highlighting the urgency of affordable insulin access.